Recent policies reflect China’s goal of promoting patients’ access to innovative drugs. Noteworthy policy items include:

  • The 2018 version of the Essential Drug List (EDL) was approved
  • National Reimbursement Drug List (NRDL) Negotiation Results Released
  • NMPA released List of Medical Devices Exempted from Clinical Trials
  • Zhang Mao was appointed as Party Secretary of the SAMR
  • NHC released Guiding Principles for Clinical Use of New Anti-Cancer Drugs (2018 Version)

Download the latest Issue Here >>

Leave a comment